Ocugen, Inc.
OCGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ocugen, Inc. focuses on Biotechnology services and products. Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. Valued at $451.0M, OCGN is a small-cap name in its sector. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Market Cap
$451.0M
Beta
2.21
P/E (TTM)
—
P/E (Fwd)
-4.99
EPS (TTM)
$-0.26
EPS (Fwd)
$-0.27
ROE
—
ROA
-48.4%
Cash
$100.1M
Total Debt
$88.0M
Free CF
-$2.0M
52W Change
30.8%
Annual Financials
Cash vs Debt
Where OCGN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OCGN finished 14.29% below its 150-day moving average ($1.54) and 12.58% below its 200-day moving average ($1.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OCGN overbought or oversold?
At the September 3, 2026 close, OCGN's RSI(14) was 46.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $100.1M in cash and $88.0M in debt, OCGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$2.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $2.5M (2022) to $4.4M (2025), reflecting a 77% increase over the period.
With a beta above 1.5, OCGN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OCGN.